scholarly journals History and Basic Principles of Photodynamic Therapy Use in Ophthalmology

2021 ◽  
Vol 5 (1) ◽  
pp. 168-176
Author(s):  
Abdul Karim Ansyori
Keyword(s):  
Photodynamic Therapy ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Pathological Myopia ◽  
Basic Principles ◽  
Age Related ◽  
Photosensitizing Agents ◽  
History Of ◽  
First Time ◽  
Photodynamic Reaction

Photodynamic therapy (PDT) is a therapy that uses drugs, called photosensitizers or photosensitizing agents, and a specific type of light. When photosensitizers are exposed to certain wavelengths of light, they produce oxygen that kills nearby cells. PDT is achieved by a photodynamic reaction induced by the excitation of a photosensitizer exposed to light. In the field of ophthalmology, PDT was approved for the first time about ten years ago for cases of age-related macular degeneration (AMD). Neovascular age-related macular degeneration (AMD) is a vision-threatening disease characterized by pathological macular neovascularization. After that, PDT was approved for use in choroidal neovascularization (CNV) cases in pathological myopia.3 This literature review aims to describe the history of PDT use and the basic principles of photodynamic therapy in ophthalmology.

Exudative Age-Related Macular Degeneration: Current Therapies and Potential Treatments

2009 ◽  
Vol 1 ◽  
pp. CMT.S2225
Author(s):  
Polly A. Quiram ◽  
Yahui Song
Keyword(s):  
Macular Degeneration ◽  
Vision Loss ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Optimal Dosing ◽  
Dosing Strategies ◽  
Current Therapies ◽  
History Of ◽  
First Time ◽  
Harmful Effects

Strategies for preventing vision loss in patients with neovascular age-related macular degeneration (ARMD) have evolved over the past decade. Whereas earlier treatments were based on thermal destruction of choroidal neovascularization (CNV), new therapies rely on targeted pharmacologic approaches to reduce the harmful effects of CNV treatment. For the first time in the history of neovascular ARMD treatment, anti-VEGF therapies have consistently improved visual acuity in a subset of patients. Clinical trials continue to investigate the optimal dosing strategies and combination therapies to better refine the treatment of this chronic and debilitating disease.

scholarly journals Incidence of elevated intraocular pressure after intravitreal injection in Japanese patients with age-related macular degeneration

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Maiko Maruyama-Inoue ◽  
Tatsuya Inoue ◽  
Shaheeda Mohamed ◽  
Yoko Kitajima ◽  
Shoko Ikeda ◽  
...  
Keyword(s):  
Risk Factors ◽  
Intraocular Pressure ◽  
Macular Degeneration ◽  
Intravitreal Injection ◽  
Odds Ratio ◽  
Japanese Patients ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Elevated Intraocular Pressure ◽  
History Of

AbstractThe purpose of this study was to report the incidence of elevated intraocular pressure (IOP) after intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) in Japanese patients with age-related macular degeneration (AMD). A retrospective study of chart review of patients who underwent ≥ 10 intravitreal anti-VEGF injections between April 2009 and December 2019 was conducted. Elevated IOP was defined as IOP ≥ 25 mmHg at one visit. Cases with elevated IOP resulting from IVI were identified. Furthermore, the association between elevated IOP and some parameters, as the risk factors that influence elevated IOP, was investigated. A total of 402 eyes of 370 patients were included in this study. Twenty-eight eyes of 26 patients (7.0%) were identified as cases with elevated IOP after IVI. The mean time of elevation after baseline was 50.6 ± 26.5 months. History of glaucoma (p = 0.021; odds ratio, 5.85), treatment modality (p = 0.019; odds ratio, 6.32), and total number of injections (p = 0.003; odds ratio, 1.03) were significantly associated with elevated IOP. A late complication of elevated IOP is associated with IVI in patients with AMD. Particularly, history of glaucoma and treat and extend regimen with frequent injections were found to be risk factors of elevated IOP.

HISTORY OF SUNLIGHT EXPOSURE IS A RISK FACTOR FOR AGE-RELATED MACULAR DEGENERATION

Retina ◽  
2016 ◽  
Vol 36 (4) ◽  
pp. 787-790 ◽  
Author(s):  
Tina Schick ◽  
Lebriz Ersoy ◽  
Yara T. E. Lechanteur ◽  
Nicole T. M. Saksens ◽  
Carel B. Hoyng ◽  
...  
Keyword(s):  
Risk Factor ◽  
Macular Degeneration ◽  
Sunlight Exposure ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
History Of
Sign in / Sign up

Export Citation Format

Share Document